PRESS-RELEASE filed Jul 30, 2026 at 06:59 ET
Phathom reported Q2 2026 net revenue of $74.3M, up 88% YoY and above the $72.7M consensus, driven by strong VOQUEZNA prescription growth. However, GAAP EPS was -$0.21, below the consensus estimate of -$0.15, and the company lowered its full-year 2026 revenue guidance to $310-325M from $320-345M, signaling a more cautious outlook despite the strong quarter. The stock is likely to trade down on the guidance cut and EPS miss, partially offset by the revenue beat and progress toward profitability.